TheraRadar
← Back
Data updated: Mar 29, 2026

Regeneron

REGN
OncologyCardiovascularDermatology
Biotech

Biotechnology leader known for Eylea (ophthalmology) and Dupixent (immunology, co-developed with Sanofi). Strong antibody discovery platform.

$14.9B
Revenue (2024)
$85.0B
Market Cap
-
Trials
16
Approved (2yr)

Key Drugs

EYLEA
aflibercept
PlGF 5 indications · 2011
DUPIXENT
dupilumab
Immunology
IL-4Rα 5 indications · 2017
PRALUENT
alirocumab
PCSK9 4 indications · 2015
EYLEA HD
aflibercept
Metabolic
PlGF 4 indications · 2023
INMAZEB
atoltivimab
Orthoebolavirus zairense 1 indications · 2020

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Competitive Matchups Pro

Loading...

Recent Activity

DUPIXENT 2026-02-23
Efficacy
EYLEA HD 2025-11-19
Efficacy
LIBTAYO 2025-10-29
Efficacy
PRALUENT 2025-10-09
Efficacy
LIBTAYO 2025-10-08
Efficacy
EVKEEZA 2025-09-25
Efficacy
DUPIXENT 2025-06-18
Efficacy
DUPIXENT 2025-04-17
Efficacy
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 53%
0 drugs Phase 3: 18 Phase 2: 26 Phase 1: 29
Cardiovascular 15%
1 drugs Phase 3: 6 Phase 2: 6 Phase 1: 2
Dermatology 13%
0 drugs Phase 3: 6 Phase 2: 4 Phase 1: 4
Ophthalmology 10%
1 drugs Phase 3: 3 Phase 2: 5 Phase 1: 1
Immunology 9%
0 drugs Phase 3: 4 Phase 2: 4 Phase 1: 2

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Novartis big-pharma
Oncology, Cardiovascular, Immunology, Ophthalmology
Baxter specialty
Cardiovascular, Oncology, Dermatology, Ophthalmology
Bayer big-pharma
Oncology, Cardiovascular, Ophthalmology, Dermatology
BAUSCH specialty
Dermatology, Immunology, Ophthalmology, Cardiovascular
Pfizer big-pharma
Oncology, Dermatology, Immunology